Développement de traitements pour les maladies génétiques causées par des mutations non-sens.
Investors 1
| Date | Name | Website |
| - | Capital Gr... | capitalgra... |
Mentions in press and media 1
| Date | Title | Description |
| 06.11.2019 | Urania Therapeutics Closes €3.5M Seed Funding | Urania Therapeutics, a Strasbourg, France-based biopharmaceutical company specializing in the identification and development of ‘readthrough’ compounds, raised €3.53M ($3.89M) in seed funding. The round was led by Advent France Biotechnolog... |